Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-05-08
2009-06-09
Szperka, Michael (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S133100, C424S185100, C424S192100, C530S388220, C530S862000, C530S868000
Reexamination Certificate
active
07544783
ABSTRACT:
This invention provides a fusion protein (FP4) and the code gene, expression method, and clinical application; its goal is to provide a fusion protein, the code gene, and the expression method as well as to take this fusion protein as the active constituent anti-allergic medicine. In addition, the invention provides the sequence of fusion protein attached on SEQ ID 2 and any derivation protein of the fusion protein (FP4) which includes adding or deleting several amino acids of SEQ ID 2 as well as increasing or deducing nuclear tides of SEQ ID 1. We designed to cross-link IgE active receptor and an IgG inhibitory receptor by endogens hinge without any extraneous chemical link. This invention fusion protein has function to block the IgE acceptor, moreover fragment of fusion protein has ability to specifically bind to a native IgG inhibitory receptor containing immunoreceptor tyrosine-based inhibitory motif, thereby inhibiting the IgE-driven mediator release from mast cells and basophils. It will play important role in the allergic disease treatment.
REFERENCES:
patent: 7265208 (2007-09-01), Saxon et al.
patent: 2003/0082190 (2003-05-01), Saxon et al.
patent: WO 02/088317 (2002-09-01), None
patent: WO 02/088317 (2002-11-01), None
patent: WO 02/102320 (2002-12-01), None
D. Zhu et al., “A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation”, Nat. Med. 8(5):5, pp. 518-521, (2002).
T. Yamada et al., <<Inhibition of interleukin-4-induced class switch recombination by a human immunoglobulin FC gamma-Fc epsilon chimeric protein, J. Biol. Chem. 278(35), pp. 32818-32824, (2003).
CL Kepley et al., “FcepsilonRI-FcgammaRII coaggregation inhibits IL-16 production from human Langerhans-like dendritic cells”, Clin. Immunol. 108(2), pp. 89-94, (2003).
Lisa Chan Allen, et al., “Modifications to Fcy-Fcε fusion protein alter its effectiveness in the inhibition of FcεRI-mediated functions”, J Allergy Clinical Immunology, pp. 1-7 (2007).
James S. Huston, et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli”, Proc. Natl. Acad. Sci. USA vol. 85, pp. 5879-5883, Aug. 1998.
Michael R. Van Scott, et al., “Systemic adminstration of an Fcy-Fcε -fusion protein in house dust mite sensitive nonhuman primates”, Clinical Immunology, vol. 128, pp. 340-348 (2008).
Chen Haiming
Gao Junyu
Jun Bao
Sughrue & Mion, PLLC
Szperka Michael
Xianggui Wu
LandOfFree
Fusion protein for treatment of allergic diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion protein for treatment of allergic diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion protein for treatment of allergic diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4062951